New drug cocktail aims to shrink untreated lymphoma tumors
NCT ID NCT07585747
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) as a first treatment for people with follicular lymphoma, a slow-growing blood cancer. The goal is to see how well the drugs shrink tumors and how safe they are. About 27 newly diagnosed adults will take part, and the study is not yet recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, Tianjin Municipality, 300020, China
-
Qilu Hospital of Shandong Province
Jinan, Shandong, China
-
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a targeted pill boost Chemotherapy's punch against lymphoma?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a targeted drug beat radiation for early-stage lymphoma?